Brought to you by
ECR 2019 / C-1035
Prediction of progression-free survival in pancreatic neuroendocrine tumours after curative surgery using MR imaging features
Congress: ECR 2019
Poster No.: C-1035
Type: Scientific Exhibit
Keywords: Abdomen, Oncology, Pancreas, MR, MR-Functional imaging, MR-Diffusion/Perfusion, Contrast agent-intravenous, Surgery, Outcomes analysis, Cancer, Endocrine disorders, Pathology
Authors: Y. Hu; Shanghai/CN



[1]  Ohmoto A, Rokutan H, Yachida S. Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future. INT J MOL SCI 2017;18(1):143.

[2]  Guilmette JM, Nose V. Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances. ADV ANAT PATHOL 2018.

[3]  Birnbaum DJ, Turrini O, Vigano L, et al. Surgical Management of Advanced Pancreatic Neuroendocrine Tumors: Short-Term and Long-Term Results from an International Multi-institutional Study. ANN SURG ONCOL 2015;22(3):1000-7.

[4]  Partelli S, Gaujoux S, Boninsegna L, et al. Pattern and Clinical Predictors of Lymph Node Involvement in Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNETs). JAMA SURG 2013;148(10):932.

[5]  Choi SH, Kim HJ, Kim SY, et al. Computed Tomography Features Predictive of Lymph Node Involvement in Patients With a Nonfunctioning Pancreatic Neuroendocrine Tumor. PANCREAS 2017;46(8):1056-63.

[6]  Karaosmanoglu AD, Onur MR, Ozmen MN, et al. Magnetic Resonance Imaging of Liver Metastasis. Seminars in Ultrasound, CT and MRI 2016;37(6):533-48.

[7]  De Robertis R, D'Onofrio M, Zamboni G, et al. Pancreatic Neuroendocrine Neoplasms: Clinical Value of Diffusion-Weighted Imaging. NEUROENDOCRINOLOGY 2016;103(6):758-70.

[8]  Al Ansari N. Role of magnetic resonance imaging in the detection and characterization of solid pancreatic nodules: An update. World Journal of Radiology 2015;7(11):361.

[9]  Canellas R, Lo G, Bhowmik S, et al. Pancreatic neuroendocrine tumor: Correlations between MRI features, tumor biology, and clinical outcome after surgery. J MAGN RESON IMAGING 2018;47(2):425-32.

[10] Nanno Y, Matsumoto I, Zen Y, et al. Pancreatic Duct Involvement in Well-Differentiated Neuroendocrine Tumors is an Independent Poor Prognostic Factor. ANN SURG ONCOL 2017;24(4):1127-33.

[11] Barral M, Sebbag-Sfez D, Hoeffel C, et al. Characterization of focal pancreatic lesions using normalized apparent diffusion  coefficient at 1.5-Tesla: preliminary experience. Diagn Interv Imaging 2013;94(6):619-27.

[12] Lotfalizadeh E, Ronot M, Wagner M, et al. Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging. EUR RADIOL 2017;27(4):1748-59.

[13] Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. PANCREAS 2010;39(6):707-12.

[14] Löhr JM, Panic N, Vujasinovic M, et al. The ageing pancreas: a systematic review of the evidence and analysis of the consequences. J INTERN MED 2018;283(5):446-60.

[15] Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. NEUROENDOCRINOLOGY 2016;103(2):153-71.

[16] Yang M, Tian BL, Zhang Y, et al. Evaluation of the World Health Organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors. PANCREAS 2014;43(7):1003-8.

[17] Hu Y, Rao S, Xu X, et al. Grade 2 pancreatic neuroendocrine tumors: overbroad scope of Ki-67 index according to MRI features. ABDOM RADIOL 2018.

[18] Scarpa A, Chang DK, Nones K, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. NATURE 2017;543(7643):65-71.

[19] Genç CG, Falconi M, Partelli S, et al. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67. ANN SURG ONCOL 2018.

[20] De Robertis R, Cingarlini S, Tinazzi Martini P, et al. Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage. WORLD J GASTROENTERO 2017;23(2):275.

[21] Sato T, Ito K, Tamada T, et al. Age-related changes in normal adult pancreas: MR imaging evaluation. EUR J RADIOL 2012;81(9):2093-8.

[22] Okabe H, Hashimoto D, Chikamoto A, et al. Shape and Enhancement Characteristics of Pancreatic Neuroendocrine Tumor on Preoperative Contrast-enhanced Computed Tomography May be Prognostic Indicators. ANN SURG ONCOL 2017;24(5):1399-405.

[23] Dick JE. Stem cell concepts renew cancer research. BLOOD 2008;112(13):4793-807.

[24] Jain RK, Martin JD, Stylianopoulos T. The Role of Mechanical Forces in Tumor Growth and Therapy. ANNU REV BIOMED ENG 2014;16(1):321-46.

[25] Yamamoto Y, Okamura Y, Uemura S, et al. Vascularity and Tumor Size are Significant Predictors for Recurrence after Resection of a Pancreatic Neuroendocrine Tumor. ANN SURG ONCOL 2017;24(8):2363-70.

[26] Hashim YM, Trinkaus KM, Linehan DC, et al. Regional Lymphadenectomy Is Indicated in the Surgical Treatment of Pancreatic Neuroendocrine Tumors (PNETs). ANN SURG 2014;259(2):197-203.

[27] Wong J, Fulp WJ, Strosberg JR, et al. Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience. The American Journal of Surgery 2014;208(5):775-80.

[28] Parekh JR, Wang SC, Bergsland EK, et al. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. PANCREAS 2012;41(6):840-4.

[29] Gao S, Pu N, Liu L, et al. The latest exploration of staging and prognostic classification for pancreatic neuroendocrine tumors: a large population-based study. J CANCER 2018;9(9):1698-706.



POSTER ACTIONS Add bookmark Contact presenter Send to a friend Download pdf
2 clicks for more privacy: On the first click the button will be activated and you can then share the poster with a second click.

This website uses cookies. Learn more